引用次数
引用: 116,318
H-指数: 150
I10-指数 : 474
出版物: 602
Time-resolved single-cell analysis of Brca1 associated mammary tumourigenesis reveals aberrant differentiation of luminal progenitors.
Karsten Bach , Sara Pensa , Marija Zarocsinceva , Katarzyna Kania
Nature Communications 12 ( 1) 1502 -1502
2
2021
PI3K activation promotes resistance to eribulin in HER2-negative breast cancer
Albert Gris-Oliver , Yasir H Ibrahim , Martín A Rivas , Celina García-García
British Journal of Cancer 124 ( 9) 1581 -1591
8
2021
Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response
Dimitra Georgopoulou , Maurizio Callari , Oscar M Rueda , Abigail Shea
Nature Communications 12 ( 1) 1998 -1998
2021
Characterisation of PALB2 tumours through whole-exome and whole-transcriptomic analyses.
Pei Sze Ng , Jia Wern Pan , Muhammad Mamduh Ahmad Zabidi , Pathmanathan Rajadurai
NPJ breast cancer 7 ( 1) 46 -46
2021
Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment
Safae Terrisse , Lisa Derosa , Valerio Iebba , François Ghiringhelli
Cell Death & Differentiation 1 -19
47
2021
Allelic expression imbalance of PIK3CA mutations is frequent in breast cancer and prognostically significant
Lizelle Correia , Ramiro Magno , Joana M Xavier , Bernardo P de Almeida
bioRxiv
2
2021
Deciphering the signaling network of breast cancer improves drug sensitivity prediction.
Marco Tognetti , Attila Gabor , Mi Yang , Valentina Cappelletti
Cell systems 12 ( 5)
2021
The integrated genomic and immune landscapes of lethal metastatic breast cancer (MBC).
Leticia De Mattos-Arruda , Stephen-John Sammut , Edith M Ross , Rachael Bashford-Rogers
Journal of Clinical Oncology 36 1009 -1009
2
2018
Sperm associated antigen 5 (SPAG5) as a predictor and monitor for response and distant relapse risk (DRR) to endocrine (ET) and chemo-therapies (CT) in oestrogen receptor positive (ER+) breast cancer (BC).
Tarek Mohamed Ahmed Abdel-Fatah , Graham Ball , Amy McCart Reid , Peter Simpson
Journal of Clinical Oncology 36 1066 -1066
2018
Abstract A51: Personalized monitoring of treatment response using Targeted Digital Sequencing of circulating tumor DNA
Bradon R McDonald , Tania Contente-Cuomo , Stephen-John Sammut , Michelle D Stephens
Clinical Cancer Research 26
2020
Abstract B02: Co-clinical trial of olaparib in breast and ovarian patient-derived tumor xenografts (PDX) enables the identification of response biomarkers
Violeta Serra , Cristina Cruz , Marta Castroviejo , Sara Gutiérrez
Clinical Cancer Research 22
2016
A retrospective study of SPAG5 expression and its clinical implications in >8,000 patients of ER positive (ER+) breast cancer (BC): Genomic, transcriptomic and protein analysis.
Tarek MA Abdel-Fatah , Devika Agarwal , Dong-Xu Liu , Roslin Russell
Journal of Clinical Oncology 34 575 -575
2016
CYP2D6 Gene Variants and Their Association with Breast Cancer Susceptibility
Jean E Abraham , Mel J Maranian , Kristy E Driver , Radka Platte
Cancer Epidemiology, Biomarkers & Prevention 20 ( 6) 1255 -1258
9
2011
Cancer Treatment in the Genomic Era.
Gary J Doherty , Michele Petruzzelli , Emma Beddowes , Saif S Ahmad
Annual Review of Biochemistry 88 ( 1) 247 -280
12
2019
DNA copy number motifs are strong and independent predictors of survival in breast cancer
Arne V Pladsen , Gro Nilsen , Oscar M Rueda , Miriam R Aure
Communications Biology 3 ( 1) 153 -153
3
2020
miR-342-5p as a Potential Regulator of HER2 Breast Cancer Cell Growth.
Evita M Lindholm , Suvi-Katri Leivonen , Eldri Undlien , Daniel Nebdal
MicroRNA (Shariqah, United Arab Emirates) 8 ( 2) 155 -165
14
2019
JARID1B Is a Luminal Lineage-Driving Oncogene in Breast Cancer
Shoji Yamamoto , Zhenhua Wu , Hege G Russnes , Shinji Takagi
Cancer Cell 25 ( 6) 762 -777
119
2014
Synaptojanin 2 is a druggable mediator of metastasis and the gene is overexpressed and amplified in breast cancer.
Nir Ben-Chetrit , David Chetrit , Roslin Russell , Cindy Koerner
Science Signaling 8 ( 360)
40
2015
Molecular genetics and the assessment of human cancers.
Carlos Caldas , Paul DP Pharoah ,
Expert Reviews in Molecular Medicine 1 ( 08) 1 -19
7
1999
Abstract P3-10-06: Combination of BET and FGFR inhibition as a rational therapeutic strategy for invasive lobular breast cancer
Darran P O'Connor , Louise Walsh , Kathryn Haley , Bruce Moran
Cancer Research 80
2020